Brief: Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives
05/02/2025 12:36
Feb 5 (Reuters) - Zenas Biopharma Inc ZBIO.O :
* ZENAS BIOPHARMA : TOPLINE RESULTS FROM PHASE 2 TRIAL IN
RELAPSING MULTIPLE SCLEROSIS (MOONSTONE) EXPECTED IN Q3 2025
* ZENAS BIOPHARMA :TOPLINE RESULTS FROM PIVOTAL PHASE 3
TRIAL IN
IMMUNOGLOBULIN G4-RELATED DISEASE (INDIGO) EXPECTED YEAR-END
2025
Source text: ID:nGNX3GBN3c
Further company coverage: ZBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zenas BioPharma
See all newsBrief: Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026
Brief: Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints